|

CAPEOX/XELOX Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

  • Sun Yat-sen University1
  • First Affiliated Hospital of Zhejiang University1

Indications

  • Cancer2
  • iTNT1
  • Oligometastases1
  • MSS1
  • PMMR1

Other2 trials

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Phase 2
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.